Myricx Bio, a UK biotech company developing a novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO), have entered into a license agreement under which Myricx will have exclusive access to an antibody discovered based on WuXi Bio’s integrated technology platforms.
 
Myricx will develop the antibody into a first-in-class ADC based on its NMTi payload platform, which has a highly differentiated profile over standard payload classes, including microtubule and topoisomerase inhibitors. Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumors. WuXi Bio will receive an upfront payment and will be eligible for development and commercialization milestones, as well as royalties on sales.
 
Myricx CEO Dr Robin Carr said, “We are delighted to have reached this agreement with WuXi Bio, one of the top biologics CRDMOs globally. We believe that combining this leading antibody with our novel NMTi-based payload will create an ADC with significant clinical differentiation in solid tumours. Based on our positive preclinical data, we believe NMTi-ADCs offer a highly differentiated mechanism of action, superb efficacy, and good tolerability across different cancer targets.”
 
Dr Chris Chen, CEO of WuXi Biologics, said, “This license agreement with Myricx is another testament of our proprietary integrated platform and the ‘R’ in our CRDMO business model. We are looking forward to enabling global clients to develop more first-in-class and best-in-class biologics drugs for the benefits of patients worldwide.”